Shanghai Henlius Biotech (HKG:2696) agreed to license its anti-cancer injection HLX15 to Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) in the US and 42 European countries.
HLX15 is a recombinant anti-CD38 fully human monoclonal antibody injection and a daratumumab biosimilar developed by the company. It is indicated for treating multiple myeloma.
Under the agreement, Dr. Reddy's Laboratories is granted the license to manufacture and commercialize HLX15 in subcutaneous and intravenous forms across 43 markets.
Dr. Reddy's Laboratories will make an upfront payment of $33 million, plus $98.6 million in milestone payments and 8% of the annual net sales as royalties, a Thursday Hong Kong bourse filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。